| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/14/2010 | WO2010005723A2 Drug loaded polymeric nanoparticles and methods of making and using same |
| 01/14/2010 | WO2010005721A2 Drug loaded polymeric nanoparticles and methods of making and using same |
| 01/14/2010 | WO2010005687A1 Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases or trauma |
| 01/14/2010 | WO2010005637A2 Electrostatically charged multi-acting nasal application, product, and method |
| 01/14/2010 | WO2010005594A1 Compositions and methods of producing ursodeoxycholic acid |
| 01/14/2010 | WO2010005580A2 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 01/14/2010 | WO2010005480A2 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 01/14/2010 | WO2010005403A1 Dermatological composition for use in the treatment and/or prevention of skin diseases |
| 01/14/2010 | WO2010005344A1 Nanosomal pharmaceutical form of a long acting preparation for treating hepatitis c (variants) |
| 01/14/2010 | WO2010005146A1 Tablet containing acanthopanax sessiliflorus and vitamin and method manufacturing thereof |
| 01/14/2010 | WO2010005133A1 Manufacturing method of collagen gel composition for bone regeneration |
| 01/14/2010 | WO2010004653A1 Eradicating agent and eradication method for helicobacter pylori |
| 01/14/2010 | WO2010004594A1 Ophthalmic compositions for treating pathologies of the posterior segment of the eye |
| 01/14/2010 | WO2010004513A2 Peptides and their use as carriers into cancer cells |
| 01/14/2010 | WO2010004287A2 Process |
| 01/14/2010 | WO2010004054A2 Construction of cell penetrating nucleic acids |
| 01/14/2010 | WO2010003691A2 BIOCONJUGATES COMPRISING Aβ-AUTOANTIBODY SPECIFIC EPITOPES FOR ACTIVE IMMUNOTHERAPY AND DIAGNOSIS OF ALZHEIMER'S DISEASE |
| 01/14/2010 | WO2010003668A2 Treatment of solid tumors with tissue inhibitors of metalloproteinases (timps) |
| 01/14/2010 | WO2010003465A2 A drug powder for inhalation administration and a process thereof |
| 01/14/2010 | WO2010003268A2 Methods and compositions for enhanced delivery of macromolecules |
| 01/14/2010 | WO2009144569A3 Hydrogel capable of containing and conveying cells |
| 01/14/2010 | WO2009142754A4 Dendritic conjugates and methods of use |
| 01/14/2010 | WO2009141050A3 Linear self-eliminating oligomers |
| 01/14/2010 | WO2009140754A8 An anti-cancer cytotoxic monoclonal antibody |
| 01/14/2010 | WO2009138396A3 Conjugates for the treatment of mesothelioma |
| 01/14/2010 | WO2009135852A3 Encapsulation of biologically active agents |
| 01/14/2010 | WO2009132050A3 Auris formulations for treating otic diseases and conditions |
| 01/14/2010 | WO2009129145A3 Sulfasalazine formulations in a biodegradable polymer carrier |
| 01/14/2010 | WO2009126256A3 Crosslinking method and crosslinked polysaccharide made thereby |
| 01/14/2010 | WO2009098147A3 Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanion for the treatment of aids |
| 01/14/2010 | WO2009080821A3 Multitarget compounds active at a ppar and cannabinoid receptor |
| 01/14/2010 | WO2009034453A3 Method for the immobilization of bioactive molecules within a polymeric substrate resistant to the stomach acids as oral drug delivery system |
| 01/14/2010 | WO2009030439A9 Method for the production of quick mineral agglomerates (mbda, micro bubbles distorted agglomerates) |
| 01/14/2010 | WO2008133709A3 Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production |
| 01/14/2010 | WO2008083312A3 Chemical linkers and cleavable substrates and conjugates thereof |
| 01/14/2010 | WO2008060778A3 Compositions having a performance indicator |
| 01/14/2010 | US20100010104 Semi-Solid Delivery Vehicle and Pharmaceutical Compositions |
| 01/14/2010 | US20100010103 Polymer encapsulation and/or binding |
| 01/14/2010 | US20100010102 Triggered release of drugs from polymer particles |
| 01/14/2010 | US20100010101 Rapid-Melt Compositions and Methods of Making Same |
| 01/14/2010 | US20100010051 Suspension concentrates |
| 01/14/2010 | US20100009926 Ph-sensitive polymeric micelles for drug delivery |
| 01/14/2010 | US20100009914 Method of protecting sensitive molecules from a photo-polymerizing environment |
| 01/14/2010 | US20100009908 Galectin 9-Polymer Conjugates |
| 01/14/2010 | US20100009004 Intraorally rapidly disintegrating tablet |
| 01/14/2010 | US20100009003 Pharmaceutical preparation to be dispersed before administration |
| 01/14/2010 | US20100008996 Inhalative and instillative use of semifluorinated alkanes as an active substance carrier in the intrapulmonary area |
| 01/14/2010 | US20100008960 Beauty/medication patch |
| 01/14/2010 | US20100008937 Targeted delivery to leukocytes using non-protein carriers |
| 01/14/2010 | US20100008913 Methods and compositions for treating platelet-related disorders |
| 01/14/2010 | US20100008855 Production and Use of Novel Peptide-Based Agents with Bispecific Antibodies |
| 01/14/2010 | US20100008854 Metal nanocomposite, preparation method and use thereof |
| 01/14/2010 | DE102008032327A1 Cosmetic or pharmaceutical preparation, useful for the topical application of polyunsaturated fatty acids, comprises polyunsaturated fatty acids, which are present in the form of vesicles, and a carrier system made from phospholipids |
| 01/14/2010 | CA2843880A1 Nutritive compositions and methods of using same |
| 01/14/2010 | CA2767331A1 Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| 01/14/2010 | CA2730391A1 Delivery of dry formulations of octreotide |
| 01/14/2010 | CA2730321A1 Process for preparing microparticles |
| 01/14/2010 | CA2730316A1 Peptide inhibitors of cd40l signaling and uses therefor |
| 01/14/2010 | CA2730308A1 Peptides and their use as carriers into cancer cells |
| 01/14/2010 | CA2730258A1 Mineral amino acid polysaccharide complex |
| 01/14/2010 | CA2730178A1 Methods and compositions for enhanced delivery of macromolecules |
| 01/14/2010 | CA2730085A1 Functional micelles for hard tissue targeted delivery of chemicals |
| 01/14/2010 | CA2729949A1 Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| 01/14/2010 | CA2729948A1 Tacrolimus for improved treatment of transplant patients |
| 01/14/2010 | CA2729852A1 Hydrophobically enhanced aminoglycosides |
| 01/14/2010 | CA2729602A1 Notch1 receptor binding agents and methods of use thereof |
| 01/14/2010 | CA2728856A1 Composition and method of preparation of release systems for constant (zero-order) release of active agents |
| 01/14/2010 | CA2728213A1 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 01/14/2010 | CA2728176A1 Drug loaded polymeric nanoparticles and methods of making and using same |
| 01/14/2010 | CA2726311A1 Electrostatically charged multi-acting nasal application, product, and method |
| 01/13/2010 | EP2143800A1 Formulations of lycopene and uses thereof |
| 01/13/2010 | EP2143736A1 Hydroxyalkyl starch derivatives |
| 01/13/2010 | EP2143726A1 Nucleic acid comprising zwitterionic nucleotides |
| 01/13/2010 | EP2143447A1 Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease |
| 01/13/2010 | EP2143446A1 Hybrid gel comprising chemically crosslinked hyaluronic acid derivative and pharmaceutical composition using the same |
| 01/13/2010 | EP2143445A1 Medicated patch |
| 01/13/2010 | EP2143442A1 Treatment of solid tumors with tissue inhibitors of metalloproteinases(TIMPs) |
| 01/13/2010 | EP2143438A1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/13/2010 | EP2143437A1 Compositions and methods for the diagnosis and treatment of tumor |
| 01/13/2010 | EP2143428A1 Tamibarotene capsule preparation |
| 01/13/2010 | EP2143424A1 Oral pharmaceutical preparation for colon-specific delivery |
| 01/13/2010 | EP2143423A1 Method for producing pulverized organic compound particle |
| 01/13/2010 | EP2142927A1 A nanoporous particle with a retained target |
| 01/13/2010 | EP2142216A1 Particle formulations and uses thereof |
| 01/13/2010 | EP2142187A2 Ibuprofen, cyclodextrines and ternary agent complexes, and pharmaceutical uses thereof |
| 01/13/2010 | EP2142186A1 Use of oligomers of lactic acid in the treatment of gynaecological disorders |
| 01/13/2010 | EP2142176A1 Compositions and methods for transmucosal delivery of domperidone |
| 01/13/2010 | EP2142174A1 Stable aqueous g-csf formulations |
| 01/13/2010 | EP2142172A2 Packaged film dosage unit containing a complexate |
| 01/13/2010 | EP2142171A2 Antifungal foam containing ciclopiroxolamine and zinc pyrithione, and medical and cosmetic applications thereof |
| 01/13/2010 | EP2142170A2 A method of producing fast dissolving tablets |
| 01/13/2010 | EP2142169A2 Aqueous pharmaceutical preparation |
| 01/13/2010 | EP1701737B1 Use of shigella invaplex to transport functional proteins and transcriptionally active nucleic acids across mammalian cell membranes in vitro and in vivo |
| 01/13/2010 | EP1646404B1 Solid composition comprising a proton pump inhibitor |
| 01/13/2010 | EP1499886B1 Methods and compositions for inducing an immune response |
| 01/13/2010 | EP1323415B1 Method of coating fine particle with lipid film |
| 01/13/2010 | EP1305322B1 Derivatives of branched-chain lipophilic molecules and uses thereof |
| 01/13/2010 | EP1255725B1 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents |
| 01/13/2010 | CN101623503A Composite of survivin and sialylLewis and preparation method and application thereof |
| 01/13/2010 | CN101623502A Ganodenic acid monomer Me cyclodextrin inclusion compound and preparation method of oral solid preparation thereof |